ReviewImmunoTargets and therapy2023
Novel Immunotherapies for Myasthenia Gravis.
Review in ImmunoTargets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons.Journal of comparative effectiveness research · 2025Pooled it
- Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study.Orphanet journal of rare diseases · 2026Article
- A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis.Therapeutic advances in neurological disorders · 2026Article
- Circulating inflammatory proteins as pathogenic mediators and potential therapeutic targets in myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- FcRn inhibitors for myasthenia gravis.The Cochrane database of systematic reviews · 2025Article
- Complement inhibitors for myasthenia gravis in adults.The Cochrane database of systematic reviews · 2025Article
- Review
- Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington's Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research.Biochemistry · 2025Review
- New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Eculizumab in refractory myasthenia gravis: a real-world single-center experience.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study.Therapeutic advances in neurological disorders · 2025Article
- Article
- Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.Frontiers in immunology · 2025Article
- Consensus guidelines on the diagnosis and management of myasthenia gravis by the Saudi Arabia Neuromuscular and Electrodiagnostic Medicine and neuromuscular specialists from the Gulf Cooperation Council region.Therapeutic advances in neurological disorders · 2025Review
- Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases.Therapeutic advances in neurological disorders · 2025Article
- Peripheral nervous system immune-related adverse events due to checkpoint inhibition.Nature reviews. Neurology · 2024Review
- Recommendations for the management of myasthenia gravis in Belgium.Acta neurologica Belgica · 2024Review
- Treating myasthenia gravis beyond the eye clinic.Eye (London, England) · 2024Review
- Selection and characterization of a peptide-based complement modulator targeting C1 of the innate immune system.RSC chemical biology · 2024Article
- Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.European journal of neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. Treatment-refractory MG and long-term toxicities of the medications have been major concerns with the conventional therapies. Advances in the immunology and pathogenesis of MG have ushered in an era of newer therapies which are more specific and efficacious. Complement inhibitors and neonatal Fc receptor blockers target disease-specific pathogenic mechanisms linked to myasthenia and have proven their efficacy in pivotal clinical studies. B cell-depleting agents, specifically rituximab, have also emerged as useful for the treatment of severe MG. Many more biologicals are in the pipeline and in diverse stages of development. This review discusses the evidence for the novel therapies and the specific issues related to their clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.